津力达颗粒联合地特胰岛素对妊娠期糖尿病患者血糖、血脂指标的影响

Effects of Jinlida granules combined with insulin detemir on blood glucose and blood lipid indexes in patients with gestational diabetes mellitus

目的 探讨津力达颗粒联合地特胰岛素治疗妊娠期糖尿病(GDM)的临床效果,以期为临床治疗方式的选择提供参考。方法 将2018年1月至2020年12月我院收治的370例GDM患者根据治疗方法的不同分为联合组(186例,地特胰岛素+津力达颗粒)和对照组(184例,地特胰岛素)。比较两组的血管细胞粘附分子-1(VCAM-1)、晚期氧化蛋白产物(AOPP)、网膜素-1、血糖指标[空腹血糖(FBG)、餐后血糖(PBG)、糖化血红蛋白(HbA1c)]、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平、预后不良事件发生情况及新生儿1 min Agpar评分。结果 治疗后,联合组的VCAM-1、AOPP、网膜素-1水平优于对照组(P<0.05)。治疗后,联合组的FBG、PBG水平及HbA1c低于对照组(P<0.05)。治疗后,联合组的TG、TC、LDL-C水平低于对照组,HDL-C水平高于对照组(P<0.05)。联合组的母体、新生儿预后不良事件总发生率低于对照组,新生儿1 min Agpar评分高于对照组(P<0.05)。结论 津力达颗粒、地特胰岛素可以协同降低GDM患者血糖、血脂水平,改善预后。

Objective To investigate the clinical effect of Jinlida granules combined with insulin detemir in the treatment of gestational diabetes mellitus(GDM), so as to provide reference for the selection of clinical treatment methods.Methods A total of 370 patients with GDM admitted in our hospital from January 2018 to December 2020 were divided into combined group(186 cases, insulin detemir + Jinlida granules) and control group(184 cases, insulin detemir)according to different treatment methods. The levels of vascular cell adhesion molecule-1(VCAM-1), advanced oxidation protein products(AOPP), omentin-1, blood glucose indexes [fasting blood glucose(FBG), postprandial blood glucose(PBG),glycosylated hemoglobin(HbA1c)], blood lipid indexes [triglyceride(TG), total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C)], occurrence of poor prognosis events and 1 min Agpar score of newborn were compared between the two groups. Results After treatment, the VCAM-1, AOPP and omentin-1levels in the combined group were better than those in the control group(P<0.05). After treatment, the FBG, PBG levels and HbA1c in the combined group were lower than those in the control group(P<0.05). After treatment, the TG, TC and LDL-C levels in the combined group were lower than those in the control group, and the HDL-C level was higher than that in the control group(P<0.05). The total incidence of maternal and neonatal poor prognosis events in the combined group were lower than those in the control group, and the 1 min Agpar score of newborn was higher than that in the control group(P <0.05). Conclusion Jinlida granules and insulin detemir can synergistically reduce the blood glucose and blood lipid levels, and improve the prognosis in GDM patients.